MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors

NCT ID: NCT00147056

Last Updated: 2025-05-01

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-08-31
• Study Completion Date: 2026-12-31

Brief Summary

The purpose of this study is to evaluate the safety of MRI-guided focused ultrasound thermal ablation of brain tumors performed through intact human skull using the ExAblate transcranial system. We will collect data to establish the basic safety of this type of treatment as the basis for later studies that will evaluate its clinical efficacy.

Detailed Description

In this non-randomized feasibility study, FUS under MRI-guidance and thermometry will be given through intact human skull to brain tumor in up to ten (10) subjects. These subjects will be followed over a 3-month period with contrast MRI and clinical exams.

The objectives are:

1. To evaluate the safety of ExAblate TcMRgFUS treatment delivered through intact human skull to the brain, during the treatment, and during the follow-up period of 3 months.

2. To evaluate the effect of thermal ablation in the target tumor with contrast MR imaging to identify viable tumor, and non-viable thermally ablated tissue.

Conditions

Brain Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ExAblate transcranial system

MR Guided Focused Ultrasound

Group Type: EXPERIMENTAL

ExAblate transcranial system

Intervention Type: DEVICE

MRI-Guided Focused Ultrasound Feasibility Study for Brain

Interventions

ExAblate transcranial system

MRI-Guided Focused Ultrasound Feasibility Study for Brain

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Men or women.

2. Age between 18 and 70 years, inclusive.

3. Able and willing to give informed consent.

4. Subjects with (newly diagnosed or recurrent) metastatic cancer for whom surgery, radiation, or radiosurgery has not been advised by the treating physician.

5. The targeted tumor tissue is located in the cerebral hemispheres, > 2.5 cm from the inner table of the skull. Non-targeted parts of the tumor may extend outside the treated tumor limits.

6. Tumor(s) are clearly defined on pre-therapy contrast enhanced MRI scans.

7. Size of the targeted portion of the tumor (i.e. prescribed Region Of Treatment) is less than 2.5 cm in diameter or 8 cm3 in volume. The non-targeted tumor tissue may exceed the targeted volume.

8. Karnofsky rating 70-100 (See Appendix A).

9. ASA score 1-2.

10. Able to communicate sensations during the ExAblate MRGFUS procedure.

11. Able to attend all study visits (i.e. life expectancy of at least 3 months).

12. At least 14 days passed since last brain surgery, or intracranial radiation therapy/radiosurgery

Exclusion Criteria

1. The subject presents with:

• Symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papaedema).

• Unstable hemodynamic status including: i. Documented myocardial infarction within six months of enrollment. ii.Symptomatic coronary artery stenosis. iii. Congestive heart disease requiring medication. iv. Anti-arrhythmic drug medication. v. Cardiac pacemaker. vi. Severe hypertension (diastolic BP > 100 on medication).

2. Anti-coagulant therapy, on medications known to increase risk of hemorrhage, (e.g.: non-steroidal anti-inflammatory drugs (NSAIDs), statins

3. TIA or stroke in the last 1 month

4. Insulin-dependent diabetes mellitus

5. Immunosuppression (corticosteroids to prevent brain edema are permitted)

6. Known sensitivity to gadolinium-DTPA

7. Contraindications to MRI such as non-MRI-compatible implanted devices

8. Large subjects not fitting comfortably into the MRI scanner

9. Difficulty laying supine and still for up to 4 hours in the MRI unit or claustrophobia

10. Untreated, uncontrolled Sleep apnea

11. Positive pregnancy test (for pre-menopausal women)

12. Known life-threatening systemic disease

13. More than 3 metastatic tumors

14. History of abnormal bleeding and coagulopathy

15. Use of Avastin in the preceding two weeks or planned use in the forthcoming two weeks and VEGF inhibitors within + 30 days of treatment

16. Patients with a history of uncontrolled seizures or who are not on anti seizure medication (e.g., Phenytoin 100 mg PO t.i.d. or Keppra 500 mg po bid) before the procedure

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

InSightec

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Brigham and Women's Hospital

Boston, Massachusetts, United States

Swedish Medical Center

Seattle, Washington, United States

Countries

United States

Related Links

http://www.insightec.com

Sponsor web page

Other Identifiers

BT002

Identifier Type: -

Identifier Source: org_study_id